Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy
Pharmaceutics · 20.11.2026 · 18 (11) · 1496
DOI: 10.3390/pharmaceutics18111496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.11.2026. Verfasst von Kun Xiao und 7 weiteren Autor:innen. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Initiative for Innovative Medicine.
Abstract (Originalsprache)
In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.
Förderung
- CAMS Initiative for Innovative Medicine
Zitieren
APA
Xiao, K., Qiu, X., Zuo, L., Zhu, Z., Li, Y., Zhang, Y., Li, B., & Shan, G. (2026). Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy. Pharmaceutics, 18(11), 1496. https://doi.org/10.3390/pharmaceutics18111496
Vancouver
Xiao K, Qiu X, Zuo L, Zhu Z, Li Y, Zhang Y, et al. Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy. Pharmaceutics. 2026;18(11):1496. doi:10.3390/pharmaceutics18111496
BibTeX
@article{Xiao2026,
author = {Xiao, Kun and Qiu, Xiaodan and Zuo, Limin and Zhu, Zhiling and Li, Yiran and Zhang, Yechun and Li, Biao and Shan, Guangzhi},
title = {Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1496},
doi = {10.3390/pharmaceutics18111496}
}
EUVIMED